869371-29-9 Usage
Uses
Used in Pharmaceutical Industry:
1-[1-(methylsulfonyl)-3-piperidinyl]methanamine(SALTDATA: HCl) serves as a crucial pharmaceutical intermediate, playing a key role in the development and synthesis of an array of drugs. Its chemical structure allows for various modifications and reactions that can lead to the creation of effective medicinal compounds.
Used in Drug Formulation:
In the formulation of pharmaceuticals, 1-[1-(methylsulfonyl)-3-piperidinyl]methanamine(SALTDATA: HCl) is used to improve the solubility and stability of the final product. The addition of a hydrogen chloride molecule to create the hydrochloride salt form is a common practice to facilitate better absorption and distribution of the drug within the body.
Used in Medical Research:
1-[1-(methylsulfonyl)-3-piperidinyl]methanamine(SALTDATA: HCl) is also utilized in medical research for exploring its potential pharmacological effects. The piperidine ring and methylsulfonyl group may contribute to the compound's interaction with biological targets, making it a subject of interest for the development of new treatments for certain medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 869371-29-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,9,3,7 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 869371-29:
(8*8)+(7*6)+(6*9)+(5*3)+(4*7)+(3*1)+(2*2)+(1*9)=219
219 % 10 = 9
So 869371-29-9 is a valid CAS Registry Number.
869371-29-9Relevant articles and documents
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 107, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
PYRROLOPYRAZINE INHIBITORS OF KINASES
-
Page/Page column 26, (2011/02/18)
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
